title: Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions.
abstract: In HIV-1-infected patients with long-term undetectable viraemia on highly active antiretroviral treatment (HAART), we found that pre-HAART plasma viraemia and the baseline proviral DNA level were significantly associated with the viraemia setpoint during scheduled treatment interruptions. In long-term treated patients, pre-HAART viraemia may not be available, and in these circumstances proviral DNA, measured at the time of scheduled treatment interruption, can help to identify patients likely to reach a low viraemia setpoint after treatment interruption.
authors.forename: Sabine
authors.initials: S
authors.lastname: Yerly
authors.forename: Huldrych F
authors.initials: HF
authors.lastname: Günthard
authors.forename: Catherine
authors.initials: C
authors.lastname: Fagard
authors.forename: Béda
authors.initials: B
authors.lastname: Joos
authors.forename: Thomas V
authors.initials: TV
authors.lastname: Perneger
authors.forename: Bernard
authors.initials: B
authors.lastname: Hirschel
authors.forename: Luc
authors.initials: L
authors.lastname: Perrin
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D004279:DNA, Viral; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D015999:Multivariate Analysis; D009154:Mutation / Q000235:genetics; D012367:RNA, Viral / Q000235:genetics; D014766:Viremia / Q000235:genetics / Q000821:virology
chemical_list: D004279:DNA, Viral; D012367:RNA, Viral